Key statistics
As of last trade, Annovis Bio Inc (ANVS:NYQ) traded at 6.73, 48.57% above the 52 week low of 4.53 set on Jul 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.85 |
---|---|
High | 6.95 |
Low | 6.72 |
Bid | 6.74 |
Offer | 6.79 |
Previous close | 6.79 |
Average volume | 235.18k |
---|---|
Shares outstanding | 13.80m |
Free float | 10.98m |
P/E (TTM) | -- |
Market cap | 93.68m USD |
EPS (TTM) | -3.76 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 19:08 GMT.
More ▼
- Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
- Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
- Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
- Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
- FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
- Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
- Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
- Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
- Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Annovis Bio Reports Second Quarter Financial Results and Provides Business Update
More ▼